Daily non-political popular news in brief.

Anthracyclines improve survival in HER2-positive breast cancer patients

12-25-2007 · EurekAlert!

Treatment with the class of chemotherapy drugs called anthracyclines improves survival in women with HER2-positive breast cancer who have previously had surgery, but it may not offer any benefit for women with HER2-negative tumors, according to a study published online Dec. 25 in the Journal of the National Cancer Institute.

Keywords: anthracyclines, improve, survival, her2-positive, breast, cancer, patients, anthracycline, her2, positive, patient

« Previous | Next »

Similar news on "Anthracyclines improve survival in HER2-positive breast cancer patients":

Gene patenting -- steep cost for health care and patients
05-07-2007 · EurekAlert!
The drug trastuzumab (Herceptin) is used to treat HER2-positive breast cancer (a type of breast cancer that overexpresses the HER2 gene and accounts for about 25 percent of all breast cancers). Trastuzumab therapy improves the chances of survival; however, it has deleterious side effects and is expensive. Thus, it is important to accurately determine the patient's HER2 status.
Similar news · Read more »
Docetaxel given after doxorubicin reduces recurrence
01-08-2008 · EurekAlert!
Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online Jan. 8 in the Journal of the National Cancer Institute.
Similar news · Read more »
Gene profiling predicts resistance to breast cancer drug Herceptin
02-20-2007 · EurekAlert!
Using gene chips to profile tumors before treatment, researchers at Harvard and Yale Universities found markers that identified breast cancer subtypes resistant to Herceptin, the primary treatment for HER2-positive breast cancer. They say this advance could help further refine therapy for the 25 to 30 percent of breast cancer patients with this class of tumor.
Similar news · Read more »
Bevacizumab found to improve survival for patients with advanced breast cancer
12-26-2007 · EurekAlert!
Inhibiting the growth of blood vessels that supply tumors slows the progression of metastatic breast cancer according to results of a large clinical trial of Avastin, an antiangiogenic therapy. The study, published in the Dec. 27 issue of the New England Journal of Medicine, found that Avastin in combination with chemotherapy significantly prolongs progression-free survival for women with breast cancer compared to chemotherapy alone.
Similar news · Read more »
Mass. General leading international trial of novel breast cancer drug
12-13-2006 · EurekAlert!
A clinical trial of a new targeted breast cancer drug, led by physicians at Massachusetts General Hospital Cancer Center, has begun enrolling patients. The TEACH (Tykerb Evaluation After CHemotherapy) trial will investigate the experimental drug Tykerb (lapatinib) in patients with early-stage, HER2-positive breast cancer who have not been treated with Herceptin, another targeted drug used for the same type of tumor.
Similar news · Read more »
Combining therapies can improve survival for early-stage breast cancer patients
04-03-2007 · EurekAlert!
Patients with early-stage breast cancer who are treated with both chemotherapy and tamoxifen have a higher survival rate than patients who receive only tamoxifen. But a combination of tamoxifen and ovarian suppression -- treatment to stop the ovaries from functioning -- did not show any additional benefits, according to two randomized clinical trials published in the April 4 Journal of the National Cancer Institute.
Similar news · Read more »
Group therapy fails to improve breast cancer survival
07-23-2007 · EurekAlert!
A follow up to a previous study on group therapy in breast cancer patients finds group therapy does not prolong the lives of women with metastatic breast cancer.
Similar news · Read more »
New biomarker predicts effectiveness of breast cancer drugs
12-07-2006 · EurekAlert!
University of Cincinnati researchers have identified a new way to predict when anti-estrogen drug therapies are inappropriate for patients with hormone-dependent breast cancer.Scientists say these findings could help physicians more accurately predict which tumors will respond to anti-estrogen therapy and improve long-term survival for breast cancer patients.
Similar news · Read more »
Drug combination shrinks breast cancer metastases in brain
12-16-2007 · EurekAlert!
A combination of a "targeted" therapy and chemotherapy shrank metastatic brain tumors by at least 50 percent in one-fifth of patients with aggressive HER2-positive breast cancer, according to data presented by Dana-Farber Cancer Institute investigators at the San Antonio Breast Cancer Symposium.
Similar news · Read more »
Cryoablation is a safe procedure for breast cancer patients, early results indicate
05-04-2007 · EurekAlert!
Ultrasound-guided cryoablation of small breast cancer may be a safe procedure associated with minimal morbidity and high patient satisfaction, according to a recent case report by radiologists at the University of Wisconsin Hospital & Clinics in Madison, WI.
Similar news · Read more »